PDF(Pubmed)
Abstract：
Romosozumab is a humanized monoclonal antibody that targets the sclerostin protein, which regulates bone formation and resorption. It is a novel therapy in the treatment of post-menopausal women with osteoporosis. The evidence regarding romosozumab\'s cardiovascular safety is conflicting. We report the first post-marketing case demonstrating cardiac events (i.e., atrial fibrillation and congestive heart failure) in a female patient with osteoporosis likely triggered by romosozumab. A literature review on romosozumab and cardiovascular disease is discussed extensively. For osteoporotic patients with cardiovascular risk factors (e.g., hypertension, coronary artery disease, and stroke), the benefits of fracture prevention should be weighed against potential cardiovascular risks before prescribing romosozumab. Real-world data on post-marketing surveillance will shed light on the potential safety signals of romosozumab.
摘要：
Romosozumab是一种针对硬化蛋白的人源化单克隆抗体，调节骨形成和吸收。它是一种治疗绝经后妇女骨质疏松症的新疗法。关于romosozumab心血管安全性的证据是相互矛盾的。我们报告了第一个上市后证明心脏事件的案例(即，房颤和充血性心力衰竭）可能由romosozumab引发的骨质疏松症女性患者。关于romosozumab和心血管疾病的文献综述被广泛讨论。对于具有心血管危险因素的骨质疏松患者(例如，高血压,冠状动脉疾病,和中风)，在处方romosozumab之前,应权衡骨折预防的益处和潜在的心血管风险.关于上市后监测的真实世界数据将揭示romosozumab的潜在安全信号。
